Follow Us

       


"Like" us on Facebook

Clinical Trials

Disease or Condition
Cancer - Non-Hodgkin Lymphoma
Title
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Description
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Yosemite/GS-US-313-0124)
IRB Number
NCT01732913
Inclusion/Notes

Please contact the research department for full eligibility details. For additional information, please click here: http://clinicaltrials.gov/ct2/show/NCT01732913

Status
Open to Enrollment
Principal Investigator
Daniel R Greenwald, MD
Contact Email
research@ccsb.org
Phone
(805) 898-2117

This is the fat footer - edit page 906 to add content.